Cath Eberlein
Impact in
-
- Lung Cancer Treatments and Mutations
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Papers in
-
- Lung Cancer Treatments and Mutations 5
-
- PI3K/AKT/mTOR signaling in cancer 7
- Cancer therapeutics and mechanisms 3
- Angiogenesis and VEGF in Cancer 3
- Co-authors
- Simon T. Barry (8 shared papers)Margaret H. Veldman-Jones (2 shared papers)Michael G. Rolf (1 shared paper)Martin Braddock (1 shared paper)Jon Curwen (1 shared paper)Susan E. Ashton (2 shared papers)Darren A.E. Cross (4 shared papers)David M. Robinson (1 shared paper)
- Journals
- Molecular Cancer Therapeutics (3 papers)Annals of Oncology (2 papers)npj Breast Cancer (2 papers)Cancer Discovery (1 paper)Angiogenesis (1 paper)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Cath Eberlein
18 papers receiving 2.4k citations
Cath Eberlein's Hit Papers
Peers
Comparison fields: 5 of 72
- Pulmonary and Respiratory Medicine 1.5k
- Oncology 1.0k
- Cancer Research 279
- Molecular Biology 1.1k
- Organic Chemistry 325
Countries citing papers authored by Cath Eberlein
This map shows the geographic impact of Cath Eberlein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cath Eberlein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cath Eberlein more than expected).
Fields of papers citing papers by Cath Eberlein
This network shows the impact of papers produced by Cath Eberlein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cath Eberlein. The network helps show where Cath Eberlein may publish in the future.
Co-authors
The 25 scholars most cited alongside Cath Eberlein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer Hit paper breakdown → | 2014 | 1867 |
| 2 | 2013 | 235 | |
| 3 | 2015 | 78 | |
| 4 | 2012 | 48 | |
| 5 | 2016 | 42 | |
| 6 | 2011 | 30 | |
| 7 | 2022 | 27 | |
| 8 | 2017 | 21 | |
| 9 | 2024 | 17 | |
| 10 | 2023 | 16 | |
| 11 | 2010 | 13 | |
| 12 | 2023 | 12 | |
| 13 | 2024 | 11 | |
| 14 | 2016 | 7 | |
| 15 | 2025 | 5 | |
| 16 | 2024 | 5 | |
| 17 | 2014 | 3 | |
| 18 | 2014 | 2 | |
| 19 | 2026 | 0 |
About Cath Eberlein
Cath Eberlein is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Genetics and Pathology and Forensic Medicine, having authored 19 papers that have together received 2.4k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (7 papers), Lung Cancer Treatments and Mutations (5 papers), HER2/EGFR in Cancer Research (5 papers), Cancer therapeutics and mechanisms (3 papers), Angiogenesis and VEGF in Cancer (3 papers), Cancer Mechanisms and Therapy (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.5k citations), Oncology (1.0k citations), Cancer Research (279 citations), Molecular Biology (1.1k citations) and Organic Chemistry (325 citations). Cath Eberlein has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Simon T. Barry, Margaret H. Veldman-Jones, Michael G. Rolf, Martin Braddock, Jon Curwen, Susan E. Ashton, Darren A.E. Cross, David M. Robinson, Molly A. Taylor and Matthew J. Martin. Their work appears in journals such as Molecular Cancer Therapeutics, Annals of Oncology, npj Breast Cancer, Cancer Discovery and Angiogenesis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.